Cosmos Pharmaceutical Corp
TSE:3349
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5 827.5
8 520.0622
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cosmos Pharmaceutical Corp
Balance Sheet
Balance Sheet Decomposition
Cosmos Pharmaceutical Corp
| Current Assets | 156.4B |
| Cash & Short-Term Investments | 51.4B |
| Receivables | 658m |
| Other Current Assets | 104.3B |
| Non-Current Assets | 328.6B |
| PP&E | 302.2B |
| Intangibles | 474m |
| Other Non-Current Assets | 25.9B |
| Current Liabilities | 216.8B |
| Accounts Payable | 181.7B |
| Other Current Liabilities | 35.2B |
| Non-Current Liabilities | 31B |
| Long-Term Debt | 22.3B |
| Other Non-Current Liabilities | 8.7B |
Balance Sheet
Cosmos Pharmaceutical Corp
| May-2015 | May-2016 | May-2017 | May-2018 | May-2019 | May-2020 | May-2021 | May-2022 | May-2023 | May-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
18 635
|
27 282
|
27 728
|
21 668
|
19 022
|
52 122
|
55 108
|
37 362
|
45 928
|
52 301
|
|
| Cash Equivalents |
18 635
|
27 282
|
27 728
|
21 668
|
19 022
|
52 122
|
55 108
|
37 362
|
45 928
|
52 301
|
|
| Total Receivables |
2 739
|
2 986
|
3 387
|
4 627
|
5 653
|
5 879
|
6 619
|
8 577
|
10 221
|
12 199
|
|
| Accounts Receivables |
25
|
28
|
22
|
91
|
398
|
108
|
100
|
198
|
452
|
637
|
|
| Other Receivables |
2 714
|
2 958
|
3 365
|
4 536
|
5 255
|
5 771
|
6 519
|
8 379
|
9 769
|
11 562
|
|
| Inventory |
34 863
|
38 227
|
40 038
|
48 749
|
53 289
|
53 560
|
60 549
|
66 363
|
77 479
|
86 173
|
|
| Other Current Assets |
2 185
|
2 410
|
2 596
|
2 281
|
2 421
|
2 589
|
2 849
|
3 169
|
3 457
|
3 660
|
|
| Total Current Assets |
58 422
|
70 905
|
73 749
|
77 325
|
80 385
|
114 150
|
125 125
|
115 471
|
137 085
|
154 333
|
|
| PP&E Net |
93 772
|
114 463
|
134 450
|
153 976
|
172 816
|
185 374
|
195 131
|
225 286
|
259 464
|
295 798
|
|
| PP&E Gross |
93 772
|
114 463
|
134 450
|
153 976
|
172 816
|
185 374
|
195 131
|
225 286
|
259 464
|
295 798
|
|
| Accumulated Depreciation |
25 539
|
33 726
|
43 215
|
53 347
|
63 335
|
73 865
|
84 359
|
96 695
|
109 906
|
126 322
|
|
| Intangible Assets |
489
|
332
|
215
|
295
|
287
|
268
|
326
|
433
|
547
|
497
|
|
| Long-Term Investments |
31
|
8
|
4
|
5
|
4
|
5
|
5
|
4
|
4
|
4
|
|
| Other Long-Term Assets |
16 204
|
16 887
|
17 273
|
19 008
|
20 069
|
20 486
|
20 731
|
21 858
|
23 867
|
25 914
|
|
| Total Assets |
168 918
N/A
|
202 595
+20%
|
225 691
+11%
|
250 609
+11%
|
273 561
+9%
|
320 283
+17%
|
341 318
+7%
|
363 052
+6%
|
420 967
+16%
|
476 546
+13%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
70 773
|
82 472
|
91 735
|
105 062
|
110 796
|
136 532
|
133 041
|
139 224
|
161 852
|
179 549
|
|
| Accrued Liabilities |
3 971
|
3 870
|
5 415
|
5 088
|
5 832
|
8 147
|
7 504
|
6 456
|
8 516
|
10 083
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
5 395
|
6 569
|
6 270
|
5 029
|
3 177
|
3 092
|
3 095
|
3 056
|
4 485
|
6 512
|
|
| Other Current Liabilities |
9 485
|
10 546
|
10 712
|
11 257
|
13 365
|
14 179
|
15 897
|
13 327
|
17 200
|
17 085
|
|
| Total Current Liabilities |
89 624
|
103 457
|
114 132
|
126 436
|
133 170
|
161 950
|
159 537
|
162 063
|
192 053
|
213 229
|
|
| Long-Term Debt |
11 734
|
20 099
|
15 504
|
12 172
|
10 698
|
9 029
|
7 349
|
6 357
|
13 716
|
27 551
|
|
| Other Liabilities |
2 505
|
2 860
|
3 002
|
3 113
|
3 404
|
3 629
|
3 854
|
4 125
|
4 126
|
4 324
|
|
| Total Liabilities |
103 863
N/A
|
126 416
+22%
|
132 638
+5%
|
141 721
+7%
|
147 272
+4%
|
174 608
+19%
|
170 740
-2%
|
172 545
+1%
|
209 895
+22%
|
245 104
+17%
|
|
| Equity | |||||||||||
| Common Stock |
4 178
|
4 178
|
4 178
|
4 178
|
4 178
|
4 178
|
4 178
|
4 178
|
4 178
|
4 178
|
|
| Retained Earnings |
56 548
|
67 745
|
84 575
|
100 426
|
117 829
|
137 185
|
162 065
|
181 954
|
202 485
|
222 284
|
|
| Additional Paid In Capital |
4 610
|
4 610
|
4 610
|
4 610
|
4 610
|
4 610
|
4 610
|
4 610
|
4 610
|
5 101
|
|
| Unrealized Security Profit/Loss |
15
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Treasury Stock |
236
|
0
|
238
|
238
|
238
|
238
|
238
|
241
|
242
|
225
|
|
| Other Equity |
60
|
119
|
73
|
89
|
91
|
61
|
38
|
5
|
40
|
103
|
|
| Total Equity |
65 055
N/A
|
76 179
+17%
|
93 053
+22%
|
108 888
+17%
|
126 289
+16%
|
145 675
+15%
|
170 578
+17%
|
190 507
+12%
|
211 072
+11%
|
231 442
+10%
|
|
| Total Liabilities & Equity |
168 918
N/A
|
202 595
+20%
|
225 691
+11%
|
250 609
+11%
|
273 561
+9%
|
320 283
+17%
|
341 318
+7%
|
363 052
+6%
|
420 967
+16%
|
476 546
+13%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
40
|
40
|
40
|
40
|
40
|
40
|
40
|
79
|
79
|
79
|
|
You don't have any saved screeners yet
